EMD Serono creates new immuno-oncology platform

08:26 EDT 27 Jun 2013 | Pharmaceutical Business Review

EMD Serono, a subsidiary of Merck, has created a new immuno-oncology platform, which combines research, early development and biomarker strategies to advance investigational immunotherapies to fight cancer.

Original Article: EMD Serono creates new immuno-oncology platform

NEXT ARTICLE

More From BioPortfolio on "EMD Serono creates new immuno-oncology platform"

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.  Cancer sometimes begins in one part of the body before spre...

Advertisement

Searches Linking to this Story